ICAM1 and psoriasis: While there are no marketed drugs targeting ICAM1, efalizumab is an integrin alpha-L/beta-2 inhibitor which was approved for the treatment of psoriasis but then withdrawn due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (FDA.